Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
1NKEMIA A tech group providing R&D, services, training, and investment for life sciences industries.	Spain	IKM
3billion Inc. AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.	South Korea	394800
4D Molecular Therapeutics, Inc. Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.	United States of America	FDMT
AbCellera Biologics Inc. An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.	United States of America	ABCL
AbClon Inc. Develops antibody therapeutics and CAR-T for oncology and provides CRO services.	South Korea	174900
ABION Inc. Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.	South Korea	203400
Abivax S.A. Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.	United States of America	ABVX
ABL Bio Inc. Develops bispecific antibody therapies for oncology and neurodegenerative diseases.	South Korea	298380
Absci Corp A generative AI drug creation platform for designing and optimizing biologic therapeutics.	United States of America	ABSI
ABVC BIOPHARMA, INC. Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.	United States of America	ABVC